<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055585</url>
  </required_header>
  <id_info>
    <org_study_id>UGM_KE/FK/105/EC</org_study_id>
    <nct_id>NCT03055585</nct_id>
  </id_info>
  <brief_title>Applying Wolbachia to Eliminate Dengue</brief_title>
  <acronym>AWED</acronym>
  <official_title>A Non-blinded Cluster Randomised Controlled Trial to Assess the Efficacy of Wolbachia-infected Mosquito Deployments to Reduce Dengue Incidence in Yogyakarta, Indonesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gadjah Mada University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Tahija Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gadjah Mada University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This cluster randomised trial will evaluate the efficacy of Wolbachia-infected Aedes aegytpi
      mosquitoes in reducing dengue cases in Yogyakarta City, Indonesia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective:

      To assess the efficacy of community-based deployments of Wolbachia-infected Aedes aegypti
      mosquitoes in reducing the incidence of symptomatic, virologically-confirmed dengue cases of
      any severity in Yogyakarta residents aged 3-30 years in release areas, relative to
      non-release areas.

      Secondary objectives:

        -  To measure the efficacy of the Wolbachia method in reducing the incidence of symptomatic
           virologically confirmed Zika virus and chikungunya virus infection in release areas,
           relative to non-release areas

        -  To quantify the level of human mobility within Yogyakarta City, and to estimate the
           degree to which this mobility reduces the power to measure the effect of a
           cluster-randomised intervention

      Study setting:

      The study will be conducted in Yogyakarta City and Bantul District, both located in the
      province of Yogyakarta Special Region, Indonesia.The study site is 26 km2 in size, including
      24 km2 within Yogyakarta City, and 2km2 in the adjacent Bantul District. The total population
      of the study area is approximately 350,000.

      Study design:

      A cluster randomised trial with a test-negative design will be conducted. The study site will
      be divided into 24 clusters. The intervention will be allocated using constrained block
      randomisation with a parallel 1:1 assignment of intervention and control.

      The intervention is the deployment of Wolbachia-infected Aedes aegypti mosquitoes. Wolbachia
      deployments will be conducted in intervention clusters with the aim of achieving Wolbachia
      establishment (&gt;80% mean Wolbachia prevalence in trapped mosquitoes) throughout intervention
      areas within one year.

      The impact of Wolbachia deployments on dengue incidence will be assessed by comparing the
      exposure distribution (probability of living in a Wolbachia-treated area) among
      virologically-confirmed dengue cases presenting to a network of public primary clinics
      (Puskesmas), against the exposure distribution among patients with febrile illness of
      non-arboviral aetiology presenting to the same network of clinics in the same temporal
      windows. Dengue cases and arbovirus-negative controls will be sampled concurrently from
      within the population of patients presenting with febrile illness to the study clinic
      network, with case or control status classified retrospectively based on the results of
      laboratory diagnostic testing.

      Power calculations estimate that approximately 1000 dengue cases and 4000 arbovirus-negative
      time-matched controls will be needed to detect a 50% or greater reduction in dengue incidence
      in Wolbachia-treated clusters compared to untreated clusters, with 80% power. These
      estimations are dependent upon assumptions regarding the expected distribution of cases and
      controls across clusters during the study period. As dengue distribution can fluctuate
      substantially from year to year, the required sample size will be re-calculated after 50% of
      the target recruitment is completed (n=500 dengue cases), using the observed distribution of
      participants in the untreated arm. Enrolment will continue for 24 months, or longer if
      required to achieve the minimum sample size.

      Participant selection:

      Cases and controls will be enrolled from within the population of patients presenting with
      undifferentiated fever of 1-4 days duration, to one of the participating local health clinics
      (Puskesmas).

      All patients meeting the eligibility criteria will be invited to participate in the study.
      From baseline historical data we expect approximately 5000 participants per annum to be
      enrolled, among which 10-20% will be subsequently classified as virologically confirmed
      dengue.

      Enrolment will continue for 24 months, or longer if required to achieve the minimum sample
      size. Recruitment will continue for 24 months even if the estimated minimum required sample
      size is reached before this time.

      Analysis plan:

      Permutation tests and standard regression models (including the Cox proportional hazards
      model with shared frailty) will be used to estimate the relative risk and relative hazard
      (incidence rate ratio) of dengue in Wolbachia-treated versus untreated clusters, accounting
      for time-matching of cases and controls and the non-independence of study participants
      resident in the same intervention cluster.

      The intention-to-treat analysis will consider Wolbachia exposure as binary depending on the
      allocation of the cluster of residence.

      The per-protocol analysis will consider Wolbachia exposure as a weighted index based on
      Wolbachia prevalence in trapped mosquitoes in the cluster of residence and other clusters
      visited during the ten days prior to illness onset.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dengue incidence rate ratio in Wolbachia-treated versus untreated clusters</measure>
    <time_frame>24 months participant enrolment</time_frame>
    <description>Symptomatic, virologically-confirmed dengue virus (DENV) infection of any severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Zika incidence rate ratio in Wolbachia-treated versus untreated clusters</measure>
    <time_frame>24 months participant enrolment</time_frame>
    <description>Symptomatic, virologically-confirmed Zika virus (ZIKV) infection of any severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chikungunya incidence rate ratio in Wolbachia-treated versus untreated clusters</measure>
    <time_frame>24 months participant enrolment</time_frame>
    <description>Symptomatic, virologically-confirmed Chikungunya virus (CHIKV) infection of any severity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Dengue</condition>
  <condition>Zika Virus Infection</condition>
  <condition>Chikungunya Fever</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deployment of Wolbachia-infected Aedes aegypti mosquitoes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparison arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard practice dengue control activities</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Wolbachia-infected Aedes aegypti mosquitoes</intervention_name>
    <description>Deployment of Wolbachia-infected Aedes aegypti mosquitoes</description>
    <arm_group_label>Intervention arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard practice dengue control</intervention_name>
    <description>standard practice dengue control activities conducted by dengue control program</description>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_label>Comparison arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fever (either self-reported or objectively measured, e.g. (tympanic membrane
             temperature ≥38oC)) of 1-4 days duration, and where onset was prior to the day of
             presentation

          -  Aged between 3-30 years old

          -  Resided in the study area every night for the 10 days preceding illness onset

        Exclusion Criteria:

          -  Localising features suggestive of an alternative diagnosis e.g. severe diarrhea,
             otitis, pneumonia

          -  Prior enrollment in the study within the previous 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adi Utarini, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Universitas Gadjah Mada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Riris A Ahmad, MD, PhD</last_name>
    <phone>+62 274 547 147</phone>
    <email>riris.andono@eliminatedengue.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Citra Indriani, MD, MPH</last_name>
    <phone>+62 274 547 147</phone>
    <email>citra.indriani@eliminatedengue.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine, Universitas Gadjah Mada</name>
      <address>
        <city>Yogyakarta</city>
        <state>DIY</state>
        <zip>55281</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Riris A Ahmad, MD, PhD</last_name>
      <phone>+62 274 547 147</phone>
      <email>riris.andono@eliminatedengue.com</email>
    </contact>
    <contact_backup>
      <last_name>Citra Indriani, MD, MPH</last_name>
      <phone>+62 274 547 147</phone>
      <email>citra.indriani@eliminatedengue.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, Moyes CL, Farlow AW, Scott TW, Hay SI. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis. 2012;6(8):e1760. doi: 10.1371/journal.pntd.0001760. Epub 2012 Aug 7.</citation>
    <PMID>22880140</PMID>
  </reference>
  <reference>
    <citation>Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. The global distribution and burden of dengue. Nature. 2013 Apr 25;496(7446):504-7. doi: 10.1038/nature12060. Epub 2013 Apr 7.</citation>
    <PMID>23563266</PMID>
  </reference>
  <reference>
    <citation>Shepard DS, Coudeville L, Halasa YA, Zambrano B, Dayan GH. Economic impact of dengue illness in the Americas. Am J Trop Med Hyg. 2011 Feb;84(2):200-7. doi: 10.4269/ajtmh.2011.10-0503.</citation>
    <PMID>21292885</PMID>
  </reference>
  <reference>
    <citation>Shepard DS, Undurraga EA, Halasa YA. Economic and disease burden of dengue in Southeast Asia. PLoS Negl Trop Dis. 2013;7(2):e2055. doi: 10.1371/journal.pntd.0002055. Epub 2013 Feb 21. Review.</citation>
    <PMID>23437406</PMID>
  </reference>
  <reference>
    <citation>Shepard DS, Suaya JA, Halstead SB, Nathan MB, Gubler DJ, Mahoney RT, Wang DN, Meltzer MI. Cost-effectiveness of a pediatric dengue vaccine. Vaccine. 2004 Mar 12;22(9-10):1275-80.</citation>
    <PMID>15003657</PMID>
  </reference>
  <reference>
    <citation>Dengue Vaccine Initiative. Dengue vaccine candidates in clinical development. (2016). Available at: http://www.denguevaccines.org/vaccine-development. (Accessed: 13th June 2016)</citation>
  </reference>
  <reference>
    <citation>L'Azou M, Moureau A, Sarti E, Nealon J, Zambrano B, Wartel TA, Villar L, Capeding MR, Ochiai RL; CYD14 Primary Study Group; CYD15 Primary Study Group. Symptomatic Dengue in Children in 10 Asian and Latin American Countries. N Engl J Med. 2016 Mar 24;374(12):1155-66. doi: 10.1056/NEJMoa1503877.</citation>
    <PMID>27007959</PMID>
  </reference>
  <reference>
    <citation>Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A; CYD14 Study Group. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014 Oct 11;384(9951):1358-65. doi: 10.1016/S0140-6736(14)61060-6. Epub 2014 Jul 10.</citation>
    <PMID>25018116</PMID>
  </reference>
  <reference>
    <citation>Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramírez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Miranda Montoya MC, Cortés Supelano M, Zambrano B, Langevin E, Boaz M, Tornieporth N, Saville M, Noriega F; CYD15 Study Group. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015 Jan 8;372(2):113-23. doi: 10.1056/NEJMoa1411037. Epub 2014 Nov 3.</citation>
    <PMID>25365753</PMID>
  </reference>
  <reference>
    <citation>Guy B, Lang J, Saville M, Jackson N. Vaccination Against Dengue: Challenges and Current Developments. Annu Rev Med. 2016;67:387-404. doi: 10.1146/annurev-med-091014-090848. Epub 2015 Oct 23. Review.</citation>
    <PMID>26515983</PMID>
  </reference>
  <reference>
    <citation>Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cortés M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M; CYD-TDV Dengue Vaccine Working Group. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med. 2015 Sep 24;373(13):1195-206. doi: 10.1056/NEJMoa1506223. Epub 2015 Jul 27.</citation>
    <PMID>26214039</PMID>
  </reference>
  <reference>
    <citation>Schilte C, Staikowsky F, Couderc T, Madec Y, Carpentier F, Kassab S, Albert ML, Lecuit M, Michault A. Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl Trop Dis. 2013;7(3):e2137. doi: 10.1371/journal.pntd.0002137. Epub 2013 Mar 21. Erratum in: PLoS Negl Trop Dis. 2013 Mar;7(3). doi:10.1371/annotation/850ee20f-2641-46ac-b0c6-ef4ae79b6de6. Staikovsky, Frédérik [corrected to Staikowsky, Frederik].</citation>
    <PMID>23556021</PMID>
  </reference>
  <reference>
    <citation>Rolph MS, Foo SS, Mahalingam S. Emergent chikungunya virus and arthritis in the Americas. Lancet Infect Dis. 2015 Sep;15(9):1007-1008. doi: 10.1016/S1473-3099(15)00231-5.</citation>
    <PMID>26333330</PMID>
  </reference>
  <reference>
    <citation>Weaver SC, Costa F, Garcia-Blanco MA, Ko AI, Ribeiro GS, Saade G, Shi PY, Vasilakis N. Zika virus: History, emergence, biology, and prospects for control. Antiviral Res. 2016 Jun;130:69-80. doi: 10.1016/j.antiviral.2016.03.010. Epub 2016 Mar 18. Review.</citation>
    <PMID>26996139</PMID>
  </reference>
  <reference>
    <citation>World Health Organization. Outcome of the Emergency Committee regarding clusters of microcephaly and Guillain-Barre syndrome. (2016)</citation>
  </reference>
  <reference>
    <citation>World Health Organization. Mosquito (vector) control emergency response and preparedness for Zika virus. (2016). Available at: http://www.who.int/neglected_diseases/news/mosquito_vector_control_response/en/. (Accessed: 18th March 2016)</citation>
  </reference>
  <reference>
    <citation>Karyanti MR, Uiterwaal CS, Kusriastuti R, Hadinegoro SR, Rovers MM, Heesterbeek H, Hoes AW, Bruijning-Verhagen P. The changing incidence of dengue haemorrhagic fever in Indonesia: a 45-year registry-based analysis. BMC Infect Dis. 2014 Jul 26;14:412. doi: 10.1186/1471-2334-14-412.</citation>
    <PMID>25064368</PMID>
  </reference>
  <reference>
    <citation>Graham RR, Juffrie M, Tan R, Hayes CG, Laksono I, Ma'roef C, Erlin, Sutaryo, Porter KR, Halstead SB. A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. studies in 1995-1996. Am J Trop Med Hyg. 1999 Sep;61(3):412-9.</citation>
    <PMID>10497982</PMID>
  </reference>
  <reference>
    <citation>BPS - Statistics Indonesia. Badan Pusat Statistik. (2016). Available at: www.bps.go.id</citation>
  </reference>
  <reference>
    <citation>Ramadona AL, Lazuardi L, Hii YL, Holmner Å, Kusnanto H, Rocklöv J. Prediction of Dengue Outbreaks Based on Disease Surveillance and Meteorological Data. PLoS One. 2016 Mar 31;11(3):e0152688. doi: 10.1371/journal.pone.0152688. eCollection 2016.</citation>
    <PMID>27031524</PMID>
  </reference>
  <reference>
    <citation>Porter KR, Tan R, Istary Y, Suharyono W, Sutaryo, Widjaja S, Ma'Roef C, Listiyaningsih E, Kosasih H, Hueston L, McArdle J, Juffrie M. A serological study of Chikungunya virus transmission in Yogyakarta, Indonesia: evidence for the first outbreak since 1982. Southeast Asian J Trop Med Public Health. 2004 Jun;35(2):408-15.</citation>
    <PMID>15691147</PMID>
  </reference>
  <reference>
    <citation>Kosasih H, de Mast Q, Widjaja S, Sudjana P, Antonjaya U, Ma'roef C, Riswari SF, Porter KR, Burgess TH, Alisjahbana B, van der Ven A, Williams M. Evidence for endemic chikungunya virus infections in Bandung, Indonesia. PLoS Negl Trop Dis. 2013 Oct 24;7(10):e2483. doi: 10.1371/journal.pntd.0002483. eCollection 2013.</citation>
    <PMID>24205417</PMID>
  </reference>
  <reference>
    <citation>Riswari SF, Ma'roef CN, Djauhari H, Kosasih H, Perkasa A, Yudhaputri FA, Artika IM, Williams M, van der Ven A, Myint KS, Alisjahbana B, Ledermann JP, Powers AM, Jaya UA. Study of viremic profile in febrile specimens of chikungunya in Bandung, Indonesia. J Clin Virol. 2016 Jan;74:61-5. doi: 10.1016/j.jcv.2015.11.017. Epub 2015 Nov 17.</citation>
    <PMID>26679829</PMID>
  </reference>
  <reference>
    <citation>Laras K, Sukri NC, Larasati RP, Bangs MJ, Kosim R, Djauzi, Wandra T, Master J, Kosasih H, Hartati S, Beckett C, Sedyaningsih ER, Beecham HJ 3rd, Corwin AL. Tracking the re-emergence of epidemic chikungunya virus in Indonesia. Trans R Soc Trop Med Hyg. 2005 Feb;99(2):128-41.</citation>
    <PMID>15693148</PMID>
  </reference>
  <reference>
    <citation>Mulyatno KC, Susilowati H, Yamanaka A, Soegijanto S, Konishi E. Primary isolation and phylogenetic studies of Chikungunya virus from Surabaya, Indonesia. Jpn J Infect Dis. 2012;65(1):92-4.</citation>
    <PMID>22274167</PMID>
  </reference>
  <reference>
    <citation>Haddow AD, Schuh AJ, Yasuda CY, Kasper MR, Heang V, Huy R, Guzman H, Tesh RB, Weaver SC. Genetic characterization of Zika virus strains: geographic expansion of the Asian lineage. PLoS Negl Trop Dis. 2012;6(2):e1477. doi: 10.1371/journal.pntd.0001477. Epub 2012 Feb 28.</citation>
    <PMID>22389730</PMID>
  </reference>
  <reference>
    <citation>Perkasa A, Yudhaputri F, Haryanto S, Hayati RF, Ma'roef CN, Antonjaya U, Yohan B, Myint KS, Ledermann JP, Rosenberg R, Powers AM, Sasmono RT. Isolation of Zika Virus from Febrile Patient, Indonesia. Emerg Infect Dis. 2016 May;22(5):924-5. doi: 10.3201/eid2205.151915.</citation>
    <PMID>27088970</PMID>
  </reference>
  <reference>
    <citation>Kwong JC, Druce JD, Leder K. Zika virus infection acquired during brief travel to Indonesia. Am J Trop Med Hyg. 2013 Sep;89(3):516-7. doi: 10.4269/ajtmh.13-0029. Epub 2013 Jul 22.</citation>
    <PMID>23878182</PMID>
  </reference>
  <reference>
    <citation>Leung GH, Baird RW, Druce J, Anstey NM. ZIKA VIRUS INFECTION IN AUSTRALIA FOLLOWING A MONKEY BITE IN INDONESIA. Southeast Asian J Trop Med Public Health. 2015 May;46(3):460-4.</citation>
    <PMID>26521519</PMID>
  </reference>
  <reference>
    <citation>Esu E, Lenhart A, Smith L, Horstick O. Effectiveness of peridomestic space spraying with insecticide on dengue transmission; systematic review. Trop Med Int Health. 2010 May;15(5):619-31. doi: 10.1111/j.1365-3156.2010.02489.x. Epub 2010 Mar 8. Review.</citation>
    <PMID>20214764</PMID>
  </reference>
  <reference>
    <citation>Pilger, D., De Maesschalck, M., Horstick, O. &amp; San Martín, J. L. Dengue outbreak response: documented effective interventions and evidence gaps. TropIKA 1, (2010)</citation>
  </reference>
  <reference>
    <citation>Erlanger TE, Keiser J, Utzinger J. Effect of dengue vector control interventions on entomological parameters in developing countries: a systematic review and meta-analysis. Med Vet Entomol. 2008 Sep;22(3):203-21. doi: 10.1111/j.1365-2915.2008.00740.x. Review.</citation>
    <PMID>18816269</PMID>
  </reference>
  <reference>
    <citation>Bowman LR, Runge-Ranzinger S, McCall PJ. Assessing the relationship between vector indices and dengue transmission: a systematic review of the evidence. PLoS Negl Trop Dis. 2014 May 8;8(5):e2848. doi: 10.1371/journal.pntd.0002848. eCollection 2014 May. Review.</citation>
    <PMID>24810901</PMID>
  </reference>
  <reference>
    <citation>Bowman LR, Donegan S, McCall PJ. Is Dengue Vector Control Deficient in Effectiveness or Evidence?: Systematic Review and Meta-analysis. PLoS Negl Trop Dis. 2016 Mar 17;10(3):e0004551. doi: 10.1371/journal.pntd.0004551. eCollection 2016 Mar. Review.</citation>
    <PMID>26986468</PMID>
  </reference>
  <reference>
    <citation>Andersson N, Nava-Aguilera E, Arosteguí J, Morales-Perez A, Suazo-Laguna H, Legorreta-Soberanis J, Hernandez-Alvarez C, Fernandez-Salas I, Paredes-Solís S, Balmaseda A, Cortés-Guzmán AJ, Serrano de Los Santos R, Coloma J, Ledogar RJ, Harris E. Evidence based community mobilization for dengue prevention in Nicaragua and Mexico (Camino Verde, the Green Way): cluster randomized controlled trial. BMJ. 2015 Jul 8;351:h3267. doi: 10.1136/bmj.h3267.</citation>
    <PMID>26156323</PMID>
  </reference>
  <reference>
    <citation>Degener CM, Eiras AE, Azara TM, Roque RA, Rösner S, Codeço CT, Nobre AA, Rocha ES, Kroon EG, Ohly JJ, Geier M. Evaluation of the effectiveness of mass trapping with BG-sentinel traps for dengue vector control: a cluster randomized controlled trial in Manaus, Brazil. J Med Entomol. 2014 Mar;51(2):408-20.</citation>
    <PMID>24724291</PMID>
  </reference>
  <reference>
    <citation>Wilson AL, Boelaert M, Kleinschmidt I, Pinder M, Scott TW, Tusting LS, Lindsay SW. Evidence-based vector control? Improving the quality of vector control trials. Trends Parasitol. 2015 Aug;31(8):380-90. doi: 10.1016/j.pt.2015.04.015. Epub 2015 May 19. Review.</citation>
    <PMID>25999026</PMID>
  </reference>
  <reference>
    <citation>O'Neill SL, Pettigrew MM, Sinkins SP, Braig HR, Andreadis TG, Tesh RB. In vitro cultivation of Wolbachia pipientis in an Aedes albopictus cell line. Insect Mol Biol. 1997 Feb;6(1):33-9.</citation>
    <PMID>9013253</PMID>
  </reference>
  <reference>
    <citation>Stouthamer R, Breeuwer JA, Hurst GD. Wolbachia pipientis: microbial manipulator of arthropod reproduction. Annu Rev Microbiol. 1999;53:71-102. Review.</citation>
    <PMID>10547686</PMID>
  </reference>
  <reference>
    <citation>Rousset F, Vautrin D, Solignac M. Molecular identification of Wolbachia, the agent of cytoplasmic incompatibility in Drosophila simulans, and variability in relation with host mitochondrial types. Proc Biol Sci. 1992 Mar 23;247(1320):163-8.</citation>
    <PMID>1350096</PMID>
  </reference>
  <reference>
    <citation>Hilgenboecker K, Hammerstein P, Schlattmann P, Telschow A, Werren JH. How many species are infected with Wolbachia?--A statistical analysis of current data. FEMS Microbiol Lett. 2008 Apr;281(2):215-20. doi: 10.1111/j.1574-6968.2008.01110.x. Epub 2008 Feb 28.</citation>
    <PMID>18312577</PMID>
  </reference>
  <reference>
    <citation>McMeniman CJ, Lane RV, Cass BN, Fong AW, Sidhu M, Wang YF, O'Neill SL. Stable introduction of a life-shortening Wolbachia infection into the mosquito Aedes aegypti. Science. 2009 Jan 2;323(5910):141-4. doi: 10.1126/science.1165326.</citation>
    <PMID>19119237</PMID>
  </reference>
  <reference>
    <citation>Joubert DA, Walker T, Carrington LB, De Bruyne JT, Kien DH, Hoang Nle T, Chau NV, Iturbe-Ormaetxe I, Simmons CP, O'Neill SL. Establishment of a Wolbachia Superinfection in Aedes aegypti Mosquitoes as a Potential Approach for Future Resistance Management. PLoS Pathog. 2016 Feb 18;12(2):e1005434. doi: 10.1371/journal.ppat.1005434. eCollection 2016 Feb.</citation>
    <PMID>26891349</PMID>
  </reference>
  <reference>
    <citation>Walker T, Johnson PH, Moreira LA, Iturbe-Ormaetxe I, Frentiu FD, McMeniman CJ, Leong YS, Dong Y, Axford J, Kriesner P, Lloyd AL, Ritchie SA, O'Neill SL, Hoffmann AA. The wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations. Nature. 2011 Aug 24;476(7361):450-3. doi: 10.1038/nature10355.</citation>
    <PMID>21866159</PMID>
  </reference>
  <reference>
    <citation>Dutra HL, Rocha MN, Dias FB, Mansur SB, Caragata EP, Moreira LA. Wolbachia Blocks Currently Circulating Zika Virus Isolates in Brazilian Aedes aegypti Mosquitoes. Cell Host Microbe. 2016 Jun 8;19(6):771-4. doi: 10.1016/j.chom.2016.04.021. Epub 2016 May 4.</citation>
    <PMID>27156023</PMID>
  </reference>
  <reference>
    <citation>Johnson KN. The Impact of Wolbachia on Virus Infection in Mosquitoes. Viruses. 2015 Nov 4;7(11):5705-17. doi: 10.3390/v7112903. Review.</citation>
    <PMID>26556361</PMID>
  </reference>
  <reference>
    <citation>Rainey SM, Shah P, Kohl A, Dietrich I. Understanding the Wolbachia-mediated inhibition of arboviruses in mosquitoes: progress and challenges. J Gen Virol. 2014 Mar;95(Pt 3):517-30. doi: 10.1099/vir.0.057422-0. Epub 2013 Dec 16. Review.</citation>
    <PMID>24343914</PMID>
  </reference>
  <reference>
    <citation>Amuzu HE, Simmons CP, McGraw EA. Effect of repeat human blood feeding on Wolbachia density and dengue virus infection in Aedes aegypti. Parasit Vectors. 2015 Apr 24;8:246. doi: 10.1186/s13071-015-0853-y.</citation>
    <PMID>25903749</PMID>
  </reference>
  <reference>
    <citation>Ye YH, Carrasco AM, Frentiu FD, Chenoweth SF, Beebe NW, van den Hurk AF, Simmons CP, O'Neill SL, McGraw EA. Wolbachia Reduces the Transmission Potential of Dengue-Infected Aedes aegypti. PLoS Negl Trop Dis. 2015 Jun 26;9(6):e0003894. doi: 10.1371/journal.pntd.0003894. eCollection 2015.</citation>
    <PMID>26115104</PMID>
  </reference>
  <reference>
    <citation>Frentiu FD, Zakir T, Walker T, Popovici J, Pyke AT, van den Hurk A, McGraw EA, O'Neill SL. Limited dengue virus replication in field-collected Aedes aegypti mosquitoes infected with Wolbachia. PLoS Negl Trop Dis. 2014 Feb 20;8(2):e2688. doi: 10.1371/journal.pntd.0002688. eCollection 2014 Feb.</citation>
    <PMID>24587459</PMID>
  </reference>
  <reference>
    <citation>Moreira LA, Iturbe-Ormaetxe I, Jeffery JA, Lu G, Pyke AT, Hedges LM, Rocha BC, Hall-Mendelin S, Day A, Riegler M, Hugo LE, Johnson KN, Kay BH, McGraw EA, van den Hurk AF, Ryan PA, O'Neill SL. A Wolbachia symbiont in Aedes aegypti limits infection with dengue, Chikungunya, and Plasmodium. Cell. 2009 Dec 24;139(7):1268-78. doi: 10.1016/j.cell.2009.11.042.</citation>
    <PMID>20064373</PMID>
  </reference>
  <reference>
    <citation>Ferguson NM, Kien DT, Clapham H, Aguas R, Trung VT, Chau TN, Popovici J, Ryan PA, O'Neill SL, McGraw EA, Long VT, Dui le T, Nguyen HL, Chau NV, Wills B, Simmons CP. Modeling the impact on virus transmission of Wolbachia-mediated blocking of dengue virus infection of Aedes aegypti. Sci Transl Med. 2015 Mar 18;7(279):279ra37. doi: 10.1126/scitranslmed.3010370.</citation>
    <PMID>25787763</PMID>
  </reference>
  <reference>
    <citation>Wolbers M, Kleinschmidt I, Simmons CP, Donnelly CA. Considerations in the design of clinical trials to test novel entomological approaches to dengue control. PLoS Negl Trop Dis. 2012;6(11):e1937. doi: 10.1371/journal.pntd.0001937. Epub 2012 Nov 29.</citation>
    <PMID>23209869</PMID>
  </reference>
  <reference>
    <citation>Hayes, R. &amp; Moulton, L. Cluster randomized trials. (Chapman &amp; Hall/CRC, 2009)</citation>
  </reference>
  <reference>
    <citation>Endy TP, Yoon IK, Mammen MP. Prospective cohort studies of dengue viral transmission and severity of disease. Curr Top Microbiol Immunol. 2010;338:1-13. doi: 10.1007/978-3-642-02215-9_1. Review.</citation>
    <PMID>19802574</PMID>
  </reference>
  <reference>
    <citation>Vandenbroucke JP, Pearce N. Case-control studies: basic concepts. Int J Epidemiol. 2012 Oct;41(5):1480-9. doi: 10.1093/ije/dys147.</citation>
    <PMID>23045208</PMID>
  </reference>
  <reference>
    <citation>De Serres G, Skowronski DM, Wu XW, Ambrose CS. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Euro Surveill. 2013 Sep 12;18(37). pii: 20585.</citation>
    <PMID>24079398</PMID>
  </reference>
  <reference>
    <citation>Greenland S, Thomas DC. On the need for the rare disease assumption in case-control studies. Am J Epidemiol. 1982 Sep;116(3):547-53. Erratum in: Am J Epidemiol 1990 Jun;131(6):1102.</citation>
    <PMID>7124721</PMID>
  </reference>
  <reference>
    <citation>Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013 Apr 19;31(17):2165-8. doi: 10.1016/j.vaccine.2013.02.053. Epub 2013 Mar 13.</citation>
    <PMID>23499601</PMID>
  </reference>
  <reference>
    <citation>Haber M, An Q, Foppa IM, Shay DK, Ferdinands JM, Orenstein WA. A probability model for evaluating the bias and precision of influenza vaccine effectiveness estimates from case-control studies. Epidemiol Infect. 2015 May;143(7):1417-26. doi: 10.1017/S0950268814002179. Epub 2014 Aug 22.</citation>
    <PMID>25147970</PMID>
  </reference>
  <reference>
    <citation>Smith PG, Morrow RH, Ross DA, editors. Field Trials of Health Interventions: A Toolbox. 3rd edition. Oxford (UK): OUP Oxford; 2015 Jun 1.</citation>
    <PMID>26225404</PMID>
  </reference>
  <reference>
    <citation>Ivers NM, Halperin IJ, Barnsley J, Grimshaw JM, Shah BR, Tu K, Upshur R, Zwarenstein M. Allocation techniques for balance at baseline in cluster randomized trials: a methodological review. Trials. 2012 Aug 1;13:120. doi: 10.1186/1745-6215-13-120. Review.</citation>
    <PMID>22853820</PMID>
  </reference>
  <reference>
    <citation>Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol. 1971 Oct;44(526):793-7.</citation>
    <PMID>4940475</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2017</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <last_update_submitted>March 26, 2017</last_update_submitted>
  <last_update_submitted_qc>March 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gadjah Mada University</investigator_affiliation>
    <investigator_full_name>Riris Andono Ahmad</investigator_full_name>
    <investigator_title>Director of Center for Tropical Medicine, Faculty of Medicine, Universitas Gadjah Mada</investigator_title>
  </responsible_party>
  <keyword>Wolbachia; Aedes aegypti; Indonesia; Dengue; Cluster-randomised trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Dengue</mesh_term>
    <mesh_term>Chikungunya Fever</mesh_term>
    <mesh_term>Zika Virus Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

